— Research monograph
Semaglutide
The acylated GLP-1 receptor agonist benchmarked against tirzepatide in SURPASS-2.
- Class
- Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (acylated GLP-1 analog)
- Half-life (research)
- ~7 days (engineered albumin binding; pharmacokinetic literature).
- Origin
- Developed by Novo Nordisk as a structurally engineered, albumin-binding analog of native GLP-1 designed for an extended half-life. The broader GLP-1 analog field grew out of incretin physiology characterized from the 1980s onward.
- Solubility
- Water-soluble; reconstitutes in bacteriostatic water.
What is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a 31-amino-acid incretin hormone. Engineering modifications — a C18 fatty-diacid side chain that promotes reversible binding to serum albumin, plus substitutions that resist DPP-4 degradation — give it a markedly longer circulating half-life than native GLP-1, a central focus of the analog literature.
In research, semaglutide is used as a reference GLP-1 receptor agonist for studying incretin signaling, pancreatic islet biology, and energy-metabolism models. It is a regulated therapeutic in approved human channels; the Merit Sciences offering is supplied strictly for research use and not for human or veterinary administration.
How does Semaglutide work?
Selective agonism at the GLP-1 receptor, a class B G-protein-coupled receptor. Receptor engagement modulates glucose-dependent insulin secretion, glucagon release, and central pathways implicated in satiety in preclinical models.
Research applications
- GLP-1 receptor signaling research
- Incretin and islet-biology models
- Energy-metabolism and appetite-pathway studies
- Comparative GLP-1 analog pharmacology
Handling & reconstitution
Semaglutide ships as a sealed, lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water for laboratory handling. Water-soluble; reconstitutes in bacteriostatic water. Concentration equals vial mass divided by diluent volume.
Frequently asked questions
What is Semaglutide?
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a 31-amino-acid incretin hormone. Engineering modifications — a C18 fatty-diacid side chain that promotes reversible binding to serum albumin, plus substitutions that resist DPP-4 degradation — give it a markedly longer circulating half-life than native GLP-1, a central focus of the analog literature. Merit supplies it as a lyophilized research compound for research use only — not for human or veterinary use.
How does Semaglutide work?
Selective agonism at the GLP-1 receptor, a class B G-protein-coupled receptor. Receptor engagement modulates glucose-dependent insulin secretion, glucagon release, and central pathways implicated in satiety in preclinical models. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of Semaglutide?
~7 days (engineered albumin binding; pharmacokinetic literature). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit Semaglutide for human use?
No. It is sold strictly for research use only — not for human or veterinary use, and not for diagnostic or therapeutic use. Every lot ships with a certificate of analysis documenting ≥99% HPLC purity.
References
- The Discovery and Development of Liraglutide and Semaglutide. Knudsen LB, Lau J. Frontiers in Endocrinology, 2019 · doi:10.3389/fendo.2019.00155
- GLP-1 receptor agonists: mechanism of action and clinical pharmacology (review). Nauck MA, Quast DR, Wefers J, et al.. Molecular Metabolism, 2021 · doi:10.1016/j.molmet.2020.101102
For research use only. Not for human or veterinary use. Not FDA-approved. Reference information summarized from published literature — not medical or dosing advice.